| pubmed-article:9531956 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9531956 | lifeskim:mentions | umls-concept:C0242767 | lld:lifeskim |
| pubmed-article:9531956 | lifeskim:mentions | umls-concept:C0038250 | lld:lifeskim |
| pubmed-article:9531956 | lifeskim:mentions | umls-concept:C0229664 | lld:lifeskim |
| pubmed-article:9531956 | lifeskim:mentions | umls-concept:C0009392 | lld:lifeskim |
| pubmed-article:9531956 | lifeskim:mentions | umls-concept:C1186763 | lld:lifeskim |
| pubmed-article:9531956 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:9531956 | lifeskim:mentions | umls-concept:C0185112 | lld:lifeskim |
| pubmed-article:9531956 | lifeskim:mentions | umls-concept:C1521761 | lld:lifeskim |
| pubmed-article:9531956 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:9531956 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:9531956 | pubmed:dateCreated | 1998-4-21 | lld:pubmed |
| pubmed-article:9531956 | pubmed:abstractText | The use of peripheral blood progenitor cells (PBPCs) instead of autologous bone marrow leads to more rapid engraftment following high-dose chemotherapy. Mobilization regimens differ with respect to toxicity, efficiency, and cost. | lld:pubmed |
| pubmed-article:9531956 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9531956 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9531956 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9531956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9531956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9531956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9531956 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9531956 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9531956 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:9531956 | pubmed:issn | 0041-1132 | lld:pubmed |
| pubmed-article:9531956 | pubmed:author | pubmed-author:McMillanRR | lld:pubmed |
| pubmed-article:9531956 | pubmed:author | pubmed-author:MillerWW | lld:pubmed |
| pubmed-article:9531956 | pubmed:author | pubmed-author:BrehmTT | lld:pubmed |
| pubmed-article:9531956 | pubmed:author | pubmed-author:MeisenbergBB | lld:pubmed |
| pubmed-article:9531956 | pubmed:author | pubmed-author:SchmeckelAA | lld:pubmed |
| pubmed-article:9531956 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9531956 | pubmed:volume | 38 | lld:pubmed |
| pubmed-article:9531956 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9531956 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9531956 | pubmed:pagination | 209-15 | lld:pubmed |
| pubmed-article:9531956 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9531956 | pubmed:meshHeading | pubmed-meshheading:9531956-... | lld:pubmed |
| pubmed-article:9531956 | pubmed:meshHeading | pubmed-meshheading:9531956-... | lld:pubmed |
| pubmed-article:9531956 | pubmed:meshHeading | pubmed-meshheading:9531956-... | lld:pubmed |
| pubmed-article:9531956 | pubmed:meshHeading | pubmed-meshheading:9531956-... | lld:pubmed |
| pubmed-article:9531956 | pubmed:meshHeading | pubmed-meshheading:9531956-... | lld:pubmed |
| pubmed-article:9531956 | pubmed:meshHeading | pubmed-meshheading:9531956-... | lld:pubmed |
| pubmed-article:9531956 | pubmed:meshHeading | pubmed-meshheading:9531956-... | lld:pubmed |
| pubmed-article:9531956 | pubmed:meshHeading | pubmed-meshheading:9531956-... | lld:pubmed |
| pubmed-article:9531956 | pubmed:meshHeading | pubmed-meshheading:9531956-... | lld:pubmed |
| pubmed-article:9531956 | pubmed:meshHeading | pubmed-meshheading:9531956-... | lld:pubmed |
| pubmed-article:9531956 | pubmed:meshHeading | pubmed-meshheading:9531956-... | lld:pubmed |
| pubmed-article:9531956 | pubmed:meshHeading | pubmed-meshheading:9531956-... | lld:pubmed |
| pubmed-article:9531956 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9531956 | pubmed:articleTitle | A combination of low-dose cyclophosphamide and colony-stimulating factors is more cost-effective than granulocyte-colony-stimulating factors alone in mobilizing peripheral blood stem and progenitor cells. | lld:pubmed |
| pubmed-article:9531956 | pubmed:affiliation | Division of Hematology and Oncology, Scripps Clinic and Research Foundation, La Jolla, California, USA. | lld:pubmed |
| pubmed-article:9531956 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9531956 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
